From seed to process-ready raw material
We are establishing a number of grow sites around the world to supply our own production and development of medical preparations. This is where we produce and refine several different medically useful strains of Cannabis Sativa L +0.2% THC. From this raw material we then produce drugs under our own brand, but we also sell white labels on markets where we are not represented.
In 2022 we will have sufficient production capacity primarily to supply raw material to our laboratories, industry colleagues and the pharma sector worldwide. The raw material will comprise both dried plant matter, extracted liquid and kief, all of high purity.
We can see demand for safe, reasonably priced quality raw material increasing as medical cannabis expands onto more and more markets.
There are many different strains on the market, with different properties, strengths and characters. We are focusing on the varieties best suited to medical extracts, which meet end customers’ needs for relaxation or pain relief. With refinement we can also develop more efficient, sustainable and vigorous plants.
»It’s my job to manage the plantations to ensure we get a consistent, high-quality crop every time. We have experienced growers to help us, and I have also been on field trips to colleagues in the US and Canada. We use sophisticated technical solutions to maximize production and focus on sustainability.«
– Andreas Mikulic, Cultivation Manager, Aureum Agricol AB
One important aim is to build up an extensive gene pool, in seed banks and mother plants, to ensure we always have the best possible propagation material.
We are building up our number of sites and are monitoring the market environment as we move into the future. This information may therefore change over time.
Estimated start of construction in Q1 2022. We plan to build a cultivation plant of 6,000 m². The plant will be able to produce about eight to twelve tonnes of plant material per year, starting in Q4 2022.
As we have over 28,000 m² of land, we have the opportunity to grow and expand, as the market for medical cannabis grows in Europe.
In southern Africa we are looking at the possibilities of starting a cultivation facility for the production of propagating material. We have had preliminary talks with the authorities in Zambia, as we have seen that the landrace strains are some of the best cannabis genes in the world.
In connection with a possible establishment, we will look at the possibility of also launching an aid project in agriculture and health care.